title: Utilizing prognostic and predictive factors in breast cancer.
abstract: In order to make optimal treatment recommendations for patients with early-stage breast cancer, it is essential to accurately determine the patient's underlying risk of disease recurrence and choose a therapy to which the individual is most likely to respond. Lymph node status, tumor size, histopathologic features including tumor type and grade, and hormone receptor status are well-accepted prognostic factors related to breast cancer. In addition, hormone receptor status is a very strong predictor of response to hormonal therapy. However, our currently accepted prognostic and predictive factors fall short and there is a critical need to more accurately identify those most likely to require or benefit from particular therapies. Attention has therefore focused on the determination of novel prognostic and predictive factors. The most promising new factor is the level of urokinase plasminogen activator and its inhibitor plasminogen activator inhibitor. Other putative factors include proliferative rate, the presence of lymphatic or vascular invasion, human epidermal growth factor receptor 2 (HER-2/neu or erbB-2) positivity, the presence of micrometastases in lymph nodes or bone marrow, and gene expression profile by microarray analysis, and by RNA-based methodology. Data regarding potential new prognostic factors are constantly emerging. These studies are frequently challenging to interpret as they are often retrospective, based on relatively small numbers of patients, include a mix of treated and untreated women, and often do not control for other known prognostic factors. Therefore, new data must be interpreted with caution.
authors.affiliation: Georgetown University Medical Center, Lombardi Cancer Center, 3800 Reservoir Road, Washington, DC 20007, USA. dss26@gunet.georgetown.edu
authors.forename: Deepa S
authors.initials: DS
authors.lastname: Subramaniam
authors.forename: Claudine
authors.initials: C
authors.lastname: Isaacs
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D021701:Sentinel Lymph Node Biopsy; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor
references.citation: Ann Surg Oncol. 2004 Mar;11(3 Suppl):227S-30S
references.pmid: 15023757
references.citation: Semin Thromb Hemost. 1991 Jul;17(3):303-12
references.pmid: 1796300
references.citation: Cancer. 1995 Nov 15;76(10):1772-8
references.pmid: 8625046
references.citation: J Clin Oncol. 2003 Sep 15;21(18):3469-78
references.pmid: 12972522
references.citation: J Clin Oncol. 1993 Nov;11(11):2090-100
references.pmid: 8229123
references.citation: J Clin Oncol. 1997 Aug;15(8):2894-904
references.pmid: 9256133
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3808-16
references.pmid: 11559718
references.citation: J Natl Cancer Inst. 1996 Oct 16;88(20):1456-66
references.pmid: 8841020
references.citation: Br J Cancer. 2002 Feb 1;86(3):396-401
references.pmid: 11875706
references.citation: Eur J Cancer. 1994;30A(1):16-22
references.pmid: 7908213
references.citation: CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
references.pmid: 14974761
references.citation: Cancer. 1988 Aug 1;62(3):531-3
references.pmid: 3134120
references.citation: Lancet. 1999 Jul 17;354(9174):197-202
references.pmid: 10421301
references.citation: J Clin Oncol. 2001 Apr 15;19(8):2334-56
references.pmid: 11304787
references.citation: Breast Cancer Res Treat. 1992;22(3):207-19
references.pmid: 1391987
references.citation: J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8
references.pmid: 11121461
references.citation: Nature. 2002 Jan 31;415(6871):530-6
references.pmid: 11823860
references.citation: Lancet. 1998 May 16;351(9114):1451-67
references.pmid: 9605801
references.citation: Anticancer Res. 2003 Sep-Oct;23(5b):4319-24
references.pmid: 14666645
references.citation: Thromb Haemost. 2004 Mar;91(3):450-6
references.pmid: 14983219
references.citation: J Clin Oncol. 2003 May 15;21(10):1973-9
references.pmid: 12743151
references.citation: N Engl J Med. 2000 Feb 24;342(8):525-33
references.pmid: 10684910
references.citation: Histopathology. 1991 Nov;19(5):403-10
references.pmid: 1757079
references.citation: Clin Biochem. 2004 Jul;37(7):541-8
references.pmid: 15234235
references.citation: Cancer. 1989 Nov 1;64(9):1914-21
references.pmid: 2551477
references.citation: Am J Surg. 2002 Dec;184(6):492-8; discussion 498
references.pmid: 12488144
references.citation: Clin Cancer Res. 2003 Mar;9(3):923-30
references.pmid: 12631589
references.citation: J Clin Oncol. 1995 Mar;13(3):697-704
references.pmid: 7884430
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3817-27
references.pmid: 11559719
references.citation: Breast Cancer Res Treat. 1998;51(3):239-53
references.pmid: 10068082
references.citation: Breast Cancer Res Treat. 1998;52(1-3):227-37
references.pmid: 10066085
references.citation: J Clin Oncol. 1988 Jul;6(7):1076-87
references.pmid: 2856862
references.citation: J Clin Oncol. 1992 Jul;10(7):1044-8
references.pmid: 1351537
references.citation: J Natl Cancer Inst. 2002 Jan 16;94(2):116-28
references.pmid: 11792750
references.citation: Int J Cancer. 1996 Apr 22;69(2):135-41
references.pmid: 8608982
references.citation: J Clin Oncol. 1992 May;10(5):696-705
references.pmid: 1569442
references.citation: J Pathol. 1999 Jan;187(2):207-16
references.pmid: 10365096
references.citation: Cancer. 1980 Jun 15;45(12):2917-24
references.pmid: 7388735
references.citation: Cancer. 1989 Jan 1;63(1):181-7
references.pmid: 2910416
references.citation: Breast Cancer Res Treat. 1998;51(3):255-65
references.pmid: 10068083
references.citation: Br J Cancer. 1957 Sep;11(3):359-77
references.pmid: 13499785
references.citation: J Clin Oncol. 1999 May;17(5):1442-8
references.pmid: 10334529
references.citation: Lancet. 1999 Sep 11;354(9182):896-900
references.pmid: 10489948
references.citation: Semin Oncol. 2003 Oct;30(5 Suppl 16):4-13
references.pmid: 14613021
references.citation: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references.pmid: 12490681
references.citation: Clin Cancer Res. 2003 Mar;9(3):1039-46
references.pmid: 12631604
references.citation: Cancer. 2004 Dec 1;101(11):2509-15
references.pmid: 15495180
references.citation: J Clin Oncol. 2001 Feb 15;19(4):980-91
references.pmid: 11181660
references.citation: Clin Cancer Res. 1998 Jan;4(1):7-12
references.pmid: 9516946
references.citation: J Clin Oncol. 2001 Jan 15;19(2):329-35
references.pmid: 11208823
references.citation: Cancer Res. 2002 Aug 15;62(16):4617-22
references.pmid: 12183417
references.citation: J Natl Cancer Inst. 2001 Jun 20;93(12):913-20
references.pmid: 11416112
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3628-36
references.pmid: 12202663
references.citation: J Natl Cancer Inst. 2001 Jul 4;93(13):979-89
references.pmid: 11438563